Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 20
Filter
Add more filters










Publication year range
1.
Diabetes Res Clin Pract ; 174: 108740, 2021 Apr.
Article in English | MEDLINE | ID: mdl-33711397

ABSTRACT

AIMS: Olfactory dysfunction is associated with the transition from normal cognition to dementia in persons without type 2 diabetes. This study aimed to investigate whether olfactory dysfunction could be an early marker of future dementia in older patients with type 2 diabetes. METHODS: This exploratory study included 151 older Japanese outpatients with type 2 diabetes who did not have a diagnosis of probable dementia at baseline. A multivariate logistic regression model was used to determine whether Open Essence (OE) test score at baseline is associated with the development of probable dementia. RESULTS: Over 3 years, approximately 9% of the study subjects developed probable dementia. Subjects with olfactory dysfunction at baseline developed probable dementia more frequently than those without. Multivariate logistic regression showed that lower OE test score, higher age, lower Mini-Mental State Examination (MMSE) score, higher total protein concentration, and more frequent use of a sulfonylurea are significantly associated with the development of probable dementia. Stepwise multivariate regression analysis demonstrated that change in OE test score over 3 years is significantly associated with change in MMSE score. CONCLUSIONS: Our study suggested that olfactory dysfunction precedes the development of probable dementia in older patients with type 2 diabetes.


Subject(s)
Dementia/physiopathology , Diabetes Mellitus, Type 2/complications , Olfaction Disorders/complications , Aged , Aged, 80 and over , Female , Humans , Male
2.
J Endocr Soc ; 3(1): 42-51, 2019 Jan 01.
Article in English | MEDLINE | ID: mdl-30560227

ABSTRACT

CONTEXT: Accurate glucagon level measurements are necessary for investigation of mechanisms for postprandial hyperglycemia in type 2 diabetes. OBJECTIVE: To evaluate the accuracy of postprandial glucagon level measurements using a sandwich ELISA vs a recently established liquid chromatography-high resolution mass spectrometry (LC-HRMS) method in type 2 diabetes mellitus. DESIGN AND PARTICIPANTS: Twenty patients with type 2 diabetes treated with insulin underwent a meal test before and after administration of the dipeptidyl peptidase-4 inhibitor anagliptin for 4 weeks. Blood samples were taken serially after the meal, and glucagon levels were measured using both ELISA and LC-HRMS. We compared the change from baseline to 4 weeks (Δ0-4W) using the area under the curve for plasma glucagon during the meal test [area under the curve (AUC)0-3h] measured using ELISA and LC-HRMS. RESULTS: ELISA-based glucagon AUC0-3h was higher than LC-HRMS-based AUC0-3h at baseline and 4 weeks. However, differences in Δ0-4W-AUC0-3h measured using ELISA and LC-HRMS were not statistically significant. Additionally, Δ0-4W-AUC0-3h measured using ELISA and LC-HRMS were strongly correlated (r = 0.87, P < 0.001). CONCLUSIONS: Plasma glucagon levels during a meal test in patients with type 2 diabetes measured using ELISA were consistently higher than those measured using LC-HRMS. However, given that the changes in glucagon levels measured using ELISA before and after dipeptidyl peptidase-4 inhibitor therapy were similar to those based on LC-HRMS, this ELISA seems to be useful for evaluating the effect of the drug interventions on postprandial glucagon levels.

3.
PLoS One ; 12(12): e0188892, 2017.
Article in English | MEDLINE | ID: mdl-29206237

ABSTRACT

BACKGROUND & AIMS: Recently, we conducted a prospective randomized controlled trial (RCT) showing that a 6-month 130g/day low-carbohydrate diet (LCD) reduced HbA1c and BMI more than a calorie restricted diet (CRD). [1] To assess whether the benefits of the LCD persisted after the intensive intervention, we compared HbA1c and BMI between the LCD and CRD groups at 1 year after the end of the 6-month RCT. METHODS: Following the end of the 6-month RCT, patients were allowed to manage their own diets with periodic outpatient visits. One year later, we analyzed clinical and nutrition data. RESULTS: Of the 66 participants in the original study, 27 in the CRD group and 22 in the LCD group completed this trial. One year after the end of the original RCT, the carbohydrate intake was comparable between the groups (215 [189-243]/day in the CRD group and 214 (176-262) g/day in the LCD group). Compared with the baseline data, HbA1c and BMI were decreased in both groups (CRD: HbA1c -0.4 [-0.9 to 0.3] % and BMI -0.63 [-1.20 to 0.18] kg/m2; LCD: HbA1c -0.35 [-1.0 to 0.35] % and BMI -0.77 [-1.15 to -0.12] kg/m2). There were no significant differences in HbA1c and BMI between the groups. CONCLUSIONS: One year after the diet therapy intervention, the beneficial effect of the LCD on reduction of HbA1c and BMI did not persist in comparison with CRD. However, combining the data of both groups, significant improvements in HbA1c and BMI from baseline were observed. Although the superiority of the LCD disappeared 1 year after the intensive intervention, these data suggest that well-constructed nutrition therapy programs, both CRD and LCD, were equally effective in improving HbA1c for at least 1 year. TRIAL REGISTRATION: University Hospital Medical Information Network (UMIN) ID000010663.


Subject(s)
Blood Glucose/analysis , Diabetes Mellitus, Type 2/diet therapy , Dietary Carbohydrates/administration & dosage , Aged , Diabetes Mellitus, Type 2/blood , Female , Follow-Up Studies , Humans , Male , Middle Aged
4.
Expert Opin Pharmacother ; 18(18): 1921-1928, 2017 Dec.
Article in English | MEDLINE | ID: mdl-29141460

ABSTRACT

BACKGROUND: This study investigated the safety and efficacy of metformin up-titration in Japanese patients with type 2 diabetes mellitus treated with vildagliptin (100 mg/day) and low-dose metformin (500 or 750 mg/day). RESEARCH DESIGN AND METHODS: Fifty patients were randomly allocated to the control group (maintaining the initial low-dose of metformin) and the dose increase group (up-titrating of metformin to 1,500-2,250 mg/day) for 24 weeks. The primary outcome was change in HbA1c from baseline to 24 weeks. RESULTS: Among the 25 patients allocated to the dose increase group, four patients were not able to complete the study protocol because of gastrointestinal symptoms. HbA1c in the dose increase group was significantly but modestly lower than in the control group (change in HbA1c: 0.22 ± 0.57 vs. -0.15 ± 0.58%, group comparison, P < 0.05). The dose increase group did not gain weight during the study period, and no hypoglycemic events were reported in both groups. The rate of gastrointestinal symptoms in the dose increase group was profoundly higher than in the control group (32 vs. 0%, P < 0.01). CONCLUSIONS: In Japanese patients with type 2 diabetes treated with vildagliptin and low-dose metformin, metformin up-titration significantly but modestly improved glycemic control without hypoglycemia and weight gain.


Subject(s)
Adamantane/analogs & derivatives , Diabetes Mellitus, Type 2/drug therapy , Hypoglycemic Agents/therapeutic use , Metformin/therapeutic use , Nitriles/therapeutic use , Pyrrolidines/therapeutic use , Adamantane/adverse effects , Adamantane/therapeutic use , Aged , Blood Glucose/analysis , Body Weight , Drug Therapy, Combination , Female , Glycated Hemoglobin/analysis , Humans , Hypoglycemia/etiology , Japan , Male , Metformin/adverse effects , Middle Aged , Nitriles/adverse effects , Pyrrolidines/adverse effects , Treatment Outcome , Vildagliptin
5.
J Clin Med Res ; 9(3): 193-199, 2017 Mar.
Article in English | MEDLINE | ID: mdl-28179966

ABSTRACT

BACKGROUND: The aim of this study was to investigate the efficacy and safety of vildagliptin as an add-on therapy for patients with type 2 diabetes mellitus inadequately controlled with basal insulin. METHODS: Twenty-four patients treated with basal insulin and oral anti-diabetes drugs were randomly allocated into two groups: the control group (did not receive any add-on drugs) and vildagliptin group (received vildagliptin 100 mg/day for 6 months). The primary outcome was changes in hemoglobin A1c (HbA1c) from baseline to end of study. RESULTS: Treatment with vildagliptin significantly reduced HbA1c from 8.1±0.7% at baseline to 7.1±0.7% (P < 0.01), while there was no significant change of HbA1c in the control group. Vildagliptin group showed significant reduction of HbA1c compared with control group (-1.0±0.3% vs. 0.2±0.8%, P < 0.01). In addition, vildagliptin group showed a significant increase in 1,5-anhydroglucitol compared with the control group (4.5 ± 3.4 vs. 0.5 ± 4.1 µg/mL, P < 0.05). Mild hypoglycemia was reported in one patient of the vildagliptin group and two patients of the control group. CONCLUSION: Vildagliptin improved glycemic control without increasing hypoglycemia in Japanese type 2 diabetes inadequately controlled with basal insulin treatment and other oral anti-diabetes drugs. This study was registered with UMIN (University Hospital Medical Information Network ID#000010849).

6.
Clin Nutr ; 36(4): 992-1000, 2017 08.
Article in English | MEDLINE | ID: mdl-27472929

ABSTRACT

BACKGROUND & AIMS: The usefulness of low-carbohydrate diet (LCD) for Japanese patients with type 2 diabetes mellitus (T2DM) has not been fully investigated. Therefore, we compared the effectiveness and safety of LCD with calorie restricted diet (CRD). METHODS: This prospective, randomized, open-label, comparative study included 66 T2DM patients with HbA1c >7.5% even after receiving repeated education programs on CRD. They were randomly allocated to either the 130g/day LCD group (n = 33) or CRD group (n = 33). Patients received personal nutrition education of CRD or LCD for 30 min at baseline, 1, 2, 4, and 6 months. Patients of the CRD group were advised to maintain the intake of calories and balance of macronutrients (28× ideal body weight calories per day). Patients of the LCD group were advised to maintain the intake of 130 g/day carbohydrate without other specific restrictions. Several parameters were assessed at baseline and 6 months after each intervention. The primary endpoint was a change in HbA1c level from baseline to the end of the study. RESULTS: At baseline, BMI and HbA1c were 26.5 (24.6-30.1) and 8.3 (8.0-9.3), and 26.7 (25.0-30.0) kg/m2 and 8.0 (7.6-8.9) %, in the CRD and LCD, respectively. At the end of the study, HbA1c decreased by -0.65 (-1.53 to -0.10) % in the LCD group, compared with 0.00 (-0.68 to 0.40) % in the CRD group (p < 0.01). Also, the decrease in BMI in the LCD group [-0.58 (-1.51 to -0.16) kg/m2] exceeded that observed in the CRD group (p = 0.03). CONCLUSIONS: Our study demonstrated that 6-month 130 g/day LCD reduced HbA1c and BMI in poorly controlled Japanese patients with T2DM. LCD is a potentially useful nutrition therapy for Japanese patients who cannot adhere to CRD. This trial was registered at http://www.umin.ac.jp/english/ (University Hospital Medical Information Network: study ID number 000010663).


Subject(s)
Diabetes Mellitus, Type 2/diet therapy , Diet, Carbohydrate-Restricted , Diet, Diabetic , Hyperglycemia/prevention & control , Hypoglycemia/prevention & control , Patient Compliance , Precision Medicine , Aged , Body Mass Index , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/ethnology , Diet, Carbohydrate-Restricted/ethnology , Diet, Diabetic/ethnology , Diet, Reducing/ethnology , Energy Intake/ethnology , Female , Follow-Up Studies , Glycated Hemoglobin/analysis , Humans , Japan , Male , Middle Aged , Nutritional Sciences/education , Overweight/blood , Overweight/complications , Overweight/diet therapy , Overweight/ethnology , Patient Compliance/ethnology , Patient Education as Topic , Weight Loss/ethnology
7.
Int J Endocrinol ; 2015: 176261, 2015.
Article in English | MEDLINE | ID: mdl-26435713

ABSTRACT

The aim of this study was to investigate the efficacy of insulin degludec used for basal-bolus insulin regimen after switching from twice-daily basal insulin in Japanese patients with type 1 diabetes mellitus. The subjects were 22 type 1 diabetes patients treated with basal-bolus insulin regimen with twice-daily basal insulin. Basal insulin was switched to once-daily injection of insulin degludec with 10% dose reduction. HbA1c and fasting plasma glucose (FPG) were measured before and 12 weeks after switching. The frequency of hypoglycemic episodes, standard deviation (SD) of blood glucose, and mean of daily difference (MODD) were evaluated by continuous glucose monitoring (CGM) before and 4 weeks after switching. HbA1c and FPG before and 12 weeks after switching were comparable (HbA1c 8.5 ± 1.4 versus 8.7 ± 1.6%, P = 0.28; FPG 203.2 ± 81.2 versus 206.5 ± 122.4 mg/dL, P = 0.91). The frequency of hypoglycemia during nighttime was not significantly different at 4 weeks after switching (14.4 ± 17.0 versus 11.1 ± 15.0%, P = 0.45). In addition, SD and MODD before and 4 weeks after switching were also comparable. In conclusion, glycemic control under once-daily insulin degludec injection was almost comparable to that under twice-daily basal insulin injections in Japanese type 1 diabetes patients. This study was registered with ID: UMIN000010474.

8.
J Int Med Res ; 43(4): 506-17, 2015 Aug.
Article in English | MEDLINE | ID: mdl-25998626

ABSTRACT

OBJECTIVE: To analyse the relationships between dietary patterns and cognitive function in elderly patients with type 2 diabetes mellitus (T2DM). METHODS: Patients with T2DM completed a 3-day dietary record and Mini-mental State Examination (MMSE). Dietary patterns were identified by factor analysis. RESULTS: The study included 73 patients and identified five dietary patterns, one of which was characterized by high loading for vegetables and fish. A higher consumption of vegetables and fish was significantly associated with improved MMSE score (unadjusted model, model adjusted for age and sex, and model adjusted for age, sex, education, diabetic nephropathy and alcohol consumption), and decreased prevalence of suspected mild dementia (unadjusted model, model adjusted for age and sex). CONCLUSIONS: A high score in the vegetables and fish dietary pattern was associated with high MMSE score and low prevalence of suspected mild dementia in elderly patients with T2DM.


Subject(s)
Cognition , Diabetes Mellitus, Type 2/physiopathology , Diet , Aged , Aged, 80 and over , Demography , Female , Food , Humans , Male
9.
Diabetes Res Clin Pract ; 106(3): 465-73, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25451914

ABSTRACT

AIMS: Recent clinical studies identified the relation between olfactory dysfunction and cognitive impairment in the elderly without type 2 diabetes mellitus. The aim of the present study was to define the relation between olfactory function and cognition in elderly patients with type 2 diabetes mellitus. METHODS: The study participants comprised 250 elderly (age, 68-77, median 72) Japanese outpatient with type 2 diabetes mellitus free of clinically-evident cognitive impairment. Olfactory and cognitive functions were evaluated by the Open Essence (OE) test and Mini-mental State Examination (MMSE), respectively. RESULTS: Based on the MMSE score, 62.0%, 24.4%, and 13.6% of the participants were considered to have no impairment, possible cognitive impairment and probable dementia, respectively. The OE test score of the probable dementia group was significantly lower than other groups. Furthermore, age and serum uric acid were significantly higher in the probable dementia group than other groups. Simple correlation analysis showed positive correlation between the MMSE score and diastolic blood pressure, education, OE test score, total cholesterol, LDL cholesterol, folic acid, and negative correlation with age, HbA1c, aspartate aminotransferase, serum adiponectin and urinary albumin excretion. Multivariate regression analysis showed that OE test score correlated significantly and independently with MMSE score (standardized coefficients ß=0.542, R(2)=0.478, P<0.01), in addition to education level, HbA1c and serum adiponectin. CONCLUSIONS: The results suggested the association of olfactory dysfunction with cognitive impairment in elderly patients with type 2 diabetes mellitus.


Subject(s)
Cognition Disorders/etiology , Cognition/physiology , Diabetes Mellitus, Type 2/complications , Olfaction Disorders/etiology , Smell/physiology , Aged , Cognition Disorders/diagnosis , Cognition Disorders/physiopathology , Female , Humans , Male , Neuropsychological Tests , Olfaction Disorders/diagnosis , Olfaction Disorders/physiopathology , Retrospective Studies
10.
J Diabetes Investig ; 5(4): 400-9, 2014 Jul.
Article in English | MEDLINE | ID: mdl-25411599

ABSTRACT

AIMS/INTRODUCTION: To investigate the efficacy and safety of vildagliptin, a potent dipeptidyl peptidase-4 inhibitor, as add-on to nateglinide, compared with switching to vildagliptin in Japanese type 2 diabetes patients poorly controlled with nateglinide. MATERIALS AND METHODS: A total of 40 patients inadequately controlled with nateglinide were randomized to the switching group (n = 20, switching from nateglinide to vildagliptin) or combination group (n = 20, nateglinide plus vildagliptin). A meal tolerance test was carried out at weeks 0 and 24. RESULTS: The mean changes in glycated hemoglobin from baseline to week 24 were -1.2 ± 0.3% and -0.3 ± 0.5% in patients of the combination and switching groups, respectively, and the difference between the groups was statistically significant (P < 0.001). The mean changes in area under the curve of glucose from 0 to 180 min (AUC0-180 min) from baseline to week 24 was -361 ± 271.3 mmol·min/L in patients of the combination group compared with 141 ± 241.9 mmol·min/L in those of the switching group (P < 0.001). The incidence of hypoglycemic events was low (three in the combination group), and none of the patients developed severe hypoglycemia. Although the addition of vildagliptin to nateglinide did not significantly increase insulin secretion relative to glucose elevation (ISG) after meal load (ISG0-180 min: AUC0-180 min insulin / AUC0-180 min glucose) in comparison with that in baseline, the mean ISG0-30 min 24 weeks after addition of vildagliptin to nateglinide was significantly higher than that at baseline. In contrast, switching from nateglinide to vildagliptin reduced the mean ISG0-180 min, relative to baseline. CONCLUSIONS: The combination therapy of vildagliptin and nateglinide is effective and safe in Japanese type 2 diabetes, and the improved glycemic control is as a result of augmentation of nateglinide-induced early phase insulin secretion. This trial was registered with UMIN (no. ID000004010).

11.
Endocrinology ; 155(6): 2244-53, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24684300

ABSTRACT

Hypoglycemia associated with diabetes management is a potential risk for cardiovascular diseases. However, the effect of hypoglycemic episodes including a surge of sympathetic activity on the progression of neointima formation after vascular injury remains largely unknown. In this study, insulin was injected intraperitoneally into nonobese diabetic Goto-Kakizaki (GK) rats, once every 3 days for 4 weeks after balloon injury of carotid artery to induce hypoglycemia. Then, we evaluated balloon injury-induced neointima formation. Insulin treatment enhanced neointima formation and increased the number of proliferating cell nuclear antigen (PCNA)-positive cells in the carotid artery. Injection of glucose with insulin prevented hypoglycemia and abrogated intimal thickening. Also, bunazosin, an α1 adrenergic receptor antagonist, prevented intimal thickening and accumulation of PCNA-positive cells induced by insulin treatment despite the presence of concomitant hypoglycemia and high adrenaline levels. Incubation of cultured smooth muscle cells with adrenaline resulted in a significant increase in their proliferation and G0/G1 to S phase progression, which was associated with activation of extracellular signal-regulated kinase, enhanced expression of cell cycle regulatory molecules such as cyclin D1, and cyclin E, and phosphorylation of retinoblastoma protein. These adrenaline-induced effects were abrogated by bunazosin. Our data indicated that increased adrenaline induced by repetitive hypoglycemia promotes intimal thickening and smooth muscle cell proliferation after endothelial denudation in GK rats.


Subject(s)
Carotid Arteries/drug effects , Carotid Artery Injuries/pathology , Epinephrine/blood , Hypoglycemia/metabolism , Insulin/pharmacology , Neointima/chemically induced , Tunica Intima/drug effects , Animals , Carotid Artery Injuries/physiopathology , Cell Cycle/drug effects , Cell Proliferation/drug effects , Hypoglycemia/blood , Hypoglycemia/chemically induced , Male , Muscle, Smooth, Vascular/cytology , Myocytes, Smooth Muscle/cytology , Myocytes, Smooth Muscle/drug effects , Rats
12.
J Diabetes Investig ; 4(2): 202-5, 2013 Mar 18.
Article in English | MEDLINE | ID: mdl-24843653

ABSTRACT

Previous studies reported that both cilnidipine and azelnidipine have a renoprotective effect compared with amlodipine. The aim of this study was to compare the effects of cilnidipine and azelnidipine on blood pressure, heart rate and albuminuria. An open-label prospective crossover trial was carried out. We recruited 19 type 2 diabetics treated with amlodipine (5 mg/day) at least for 12 weeks. At study entry, amlodipine was changed to cilnidipine (10 mg/day) or azelnidipine (16 mg/day) and each administered for 16 weeks. Then, the drugs were switched and the treatment was continued for another 16 weeks. Despite no differences in 24-h blood pressure and heart rate between cilnidipine and azelnidipine, treatment with cilnidipine resulted in a greater reduction in urinary albumin:creatinine ratio than azelnidipine. Our results suggested that cilnidipine is more efficient in reducing albuminuria than azelnidipine independent of its blood pressure lowering effect in type 2 diabetic patients with hypertension. This trial was registered with UMIN (no. 000007201).

13.
Diabetes Care ; 35(1): 178-80, 2012 Jan.
Article in English | MEDLINE | ID: mdl-22028278

ABSTRACT

OBJECTIVE: The aim of this study was to investigate whether carotid intima-media thickness (IMT) and brachial-ankle pulse wave velocity (baPWV) add value to the Framingham risk score (FRS) in predicting the development of cardiovascular diseases (CVDs) in type 2 diabetic patients with a negative history of CVD. RESEARCH DESIGN AND METHODS: Type 2 diabetic patients (n = 783) were retrospectively recruited and followed for CVD. RESULTS: During a 5.4-year follow-up period, 85 incidences of CVD were recorded (10.9%). After adjustment for conventional arterial risk factors, multivariate analysis with the Cox proportional hazards model identified IMT, but not baPWV, as a significant determinant of CVD. In addition, the combination of FRS with IMT, but not with baPWV, improved the prediction of CVD. CONCLUSIONS: Carotid IMT is a significant predictor of CVD in asymptomatic type 2 diabetic patients, and the combination of FRS and IMT improves the prediction of CVD in these patients.


Subject(s)
Ankle Brachial Index , Cardiovascular Diseases/etiology , Carotid Intima-Media Thickness , Diabetes Mellitus, Type 2/complications , Adult , Aged , Cardiovascular Diseases/diagnostic imaging , Cardiovascular Diseases/epidemiology , Diabetes Mellitus, Type 2/diagnostic imaging , Diabetes Mellitus, Type 2/physiopathology , Female , Humans , Japan/epidemiology , Male , Middle Aged , Proportional Hazards Models , Retrospective Studies , Risk Factors
14.
Endocr J ; 56(1): 149-56, 2009.
Article in English | MEDLINE | ID: mdl-18997444

ABSTRACT

The increased flux of polyol pathway induced by hyperglycemia is implicated in the pathogenesis of various complications associated with diabetic, which results in increased oxidative stress. Because oxidative stress causes tissue damage in patients with diabetes, searching for an effective strategy to reduce oxidative stress in clinical setting is important in order to prevent diabetic complications. The aim of this study was to evaluate the effects of aldose reductase inhibition on oxidative stress in patients with type 2 diabetes mellitus. The subjects of this study were 21 patients with type 2 diabetes. We compared the levels of various oxidative stress markers and antioxidants including plasma thiobarbituric acid-reactive substances, malondialdehyde-modified low-density lipoprotein, vitamin E, beta-carotene and lipid hydroperoxides in erythrocytes at baseline with those measured after a 3-month course of epalrestat (150 mg/day), an aldose reductase inhibitor. While administration of epalrestat did not result in significant changes in plasma thiobarbituric acid-reactive substances, malondialdehyde-modified low-density lipoprotein, vitamin E, or beta-carotene, it significantly reduced lipid hydroperoxides in erythrocytes. Given the importance of measuring lipid hydroperoxides in erythrocytes as an index of oxidative stress, these results highlight the potential usefulness of epalrestat in reducing oxidative stress in type 2 diabetes mellitus.


Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Lipid Peroxidation/drug effects , Lipid Peroxides/metabolism , Rhodanine/analogs & derivatives , Thiazolidines/pharmacology , Thiazolidines/therapeutic use , Adult , Aged , Aldehyde Reductase/antagonists & inhibitors , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/metabolism , Down-Regulation/drug effects , Enzyme Inhibitors/pharmacology , Erythrocytes/drug effects , Erythrocytes/metabolism , Female , Humans , Male , Malondialdehyde/blood , Middle Aged , Oxidative Stress/drug effects , Rhodanine/pharmacology , Rhodanine/therapeutic use , Thiobarbituric Acid Reactive Substances/analysis , Thiobarbituric Acid Reactive Substances/metabolism , Vitamin E/blood , beta Carotene/blood
15.
Endocr J ; 54(5): 805-11, 2007 Dec.
Article in English | MEDLINE | ID: mdl-17895576

ABSTRACT

Anti-hypertensive agents with antioxidative effects are potentially useful for diabetic patients with hypertension to prevent the onset and progression of their complication. While dihydropyridine-type calcium antagonists are among the frequently used anti-hypertensive drugs, azelnidipine, a novel calcium antagonist, has been reported to have a unique anti-oxidative effect in vitro and in animals. In this study, we measured lipid hydroperoxides in human sample using diphenyl-1-pyrenylphosphine for the first time, and used the value of lipid hydroperoxides as an index of oxidative stress. Then, we compared the antioxidative properties of azelnidipine and amlodipine, a frequently used calcium antagonist in hypertensive diabetic patients. Administration of vitamin C and E for 8 weeks significantly reduced lipid hydroperoxides in erythrocyte membrane in normal subjects. In hypertensive diabetic patients, azelnidipine treatment for 12 weeks induced a more significant fall in erythrocyte lipid hydroperoxide level than amlodipine, though blood pressure during each treatment was comparable. Our data confirm the usefulness of lipid hydroperoxides in erythrocyte membrane as a marker of oxidative stress in vivo, and indicate that azelnidipine has a unique antioxidative property in human.


Subject(s)
Azetidinecarboxylic Acid/analogs & derivatives , Blood Pressure/drug effects , Diabetes Mellitus, Type 2/metabolism , Diabetes Mellitus, Type 2/physiopathology , Dihydropyridines/pharmacology , Dihydropyridines/therapeutic use , Hypertension/drug therapy , Lipid Peroxides/metabolism , Adult , Aged , Amlodipine/therapeutic use , Antihypertensive Agents/pharmacology , Antihypertensive Agents/therapeutic use , Ascorbic Acid/administration & dosage , Azetidinecarboxylic Acid/pharmacology , Azetidinecarboxylic Acid/therapeutic use , Calcium Channel Blockers/pharmacology , Calcium Channel Blockers/therapeutic use , Diabetes Mellitus, Type 2/complications , Erythrocytes/chemistry , Erythrocytes/drug effects , Female , Humans , Hypertension/complications , Lipid Peroxides/analysis , Male , Middle Aged , Organophosphorus Compounds/chemistry , Organophosphorus Compounds/pharmacology , Pyrenes/chemistry , Pyrenes/pharmacology , Vitamin E/administration & dosage
16.
Diabetes Res Clin Pract ; 69(3): 272-8, 2005 Sep.
Article in English | MEDLINE | ID: mdl-16098924

ABSTRACT

While carboxymethylated proteins are considered to be advanced glycation end products (AGE), they can also be induced by reactive oxygen species (ROS) independently of the AGE-forming process. To clarify whether N-(carboxymethyl)valine residues in hemoglobin (CMV-Hb) were a useful marker of the accumulation of ROS in diabetes, we evaluated CMV-Hb formation in vitro and in vivo. For the in vitro studying, purified human hemoglobin was incubated with D-glucose or D-glucose and hydrogen peroxide. For the in vivo study, CMV-Hb was extracted from peripheral red blood cells in diabetic patients and compared with that from non-diabetic subjects. Furthermore, the effect of antioxidants was evaluated after 6 months in 15 diabetic patients showing very high CMV-Hb levels. In vitro CMV-Hb formation increased in a glucose concentration and time-dependent manner. Co-incubation with glucose and hydrogen peroxide synergistically increased CMV-Hb formation. The CMV-Hb level was higher in the diabetic group than the non-diabetic group, and CMV-Hb was correlated with the plasma total cholesterol and serum creatinine levels. The CMV-Hb level was decreased by antioxidant therapy, whereas HbA1c did not change. These results demonstrate that CMV-Hb may be a useful marker for accumulation of oxidative stress in diabetic patients.


Subject(s)
Diabetes Mellitus, Type 2/blood , Hemoglobins/chemistry , Hemoglobins/physiology , Oxidative Stress/physiology , Female , Glycated Hemoglobin/metabolism , Glycation End Products, Advanced/blood , Humans , Male , Middle Aged , Reactive Oxygen Species , Valine/analysis
17.
Endocr J ; 52(3): 369-72, 2005 Jun.
Article in English | MEDLINE | ID: mdl-16006732

ABSTRACT

We report a patient in whom the administration of HMG CoA reductase inhibitors (statins) might have triggered the onset and worsening of diabetes. The patient was a 48-year-old Japanese man who underwent annual medical examination but had never been told of hyperglycemia. Four months after the commencement of atorvastatin (10 mg/day) treatment, a diagnosis of diabetes mellitus was made from his typical symptoms of hyperglycemia, postprandial plasma glucose level of 29.8 mmol/l and HbA1c of 11.5%. After 2 months of insulin therapy and 3 months after the cessation of atorvastatin, almost complete resolution of diabetes was observed. During the subsequent 3 months, diet therapy alone was sufficient to control blood glucose level. Then, we prescribed pravastatin (20 mg/day). During the subsequent 3 months, HbA1c was gradually increased. However, after discontinuation of pravastatin, HbA1c was gradually decreased. In the general population, statin does not seem to have critical adverse effects on glucose tolerance, but it may uncommonly modify the natural course of the development of diabetes in certain patients.


Subject(s)
Anticholesteremic Agents/adverse effects , Diabetes Mellitus, Type 2/chemically induced , Heptanoic Acids/adverse effects , Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects , Hypercholesterolemia/drug therapy , Pravastatin/adverse effects , Pyrroles/adverse effects , Anticholesteremic Agents/therapeutic use , Atorvastatin , Blood Glucose/drug effects , Blood Glucose/metabolism , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/therapy , Glycated Hemoglobin/metabolism , Heptanoic Acids/therapeutic use , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Hypercholesterolemia/blood , Male , Middle Aged , Pravastatin/therapeutic use , Pyrroles/therapeutic use
18.
Endocr J ; 51(4): 393-8, 2004 Aug.
Article in English | MEDLINE | ID: mdl-15351795

ABSTRACT

An open-label prospective cross-over trial was performed to compare the efficacy and safety of once daily low-dose gliclazide (20 mg/day) with that of nateglinide at the usual dosage (270 mg/day, 90 mg t.i.d.) in Japanese type 2 diabetics with relatively good glycemic control (HbA1c<7.0%). Eight patients received 20 mg/day of gliclazide and 16 received 270 mg/day of nateglinide. After at least 12 weeks of gliclazide or nateglinide therapy, the drugs were switched and treatment was continued for another 12 weeks. The final HbA1c value was modestly, but significantly, lower after gliclazide treatment than after nateglinide treatment (6.2% vs. 6.4%). However, symptoms related to hypoglycemia were significantly more common with gliclazide treatment than nateglinide treatment (7 vs. 0 cases), although there were no severe hypoglycemic events. While gliclazide acts as a free radical scavenger, there was no effect on parameters of oxidative stress such as malondialdehyde-modified low density lipoprotein and thiobarbituric acid-reactive substances at the low dosage tested. In conclusion, both drugs are reasonable options for early type 2 diabetes. Compared with the regular dose of nateglinide, 20 mg/day of gliclazide achieved modestly better glycemic control with an increased frequency of hypoglycemia in diabetic patients with relatively good glycemic control.


Subject(s)
Cyclohexanes/administration & dosage , Diabetes Mellitus, Type 2/drug therapy , Gliclazide/administration & dosage , Hypoglycemic Agents/administration & dosage , Phenylalanine/analogs & derivatives , Phenylalanine/administration & dosage , Adult , Cross-Over Studies , Cyclohexanes/adverse effects , Deoxyglucose/blood , Diabetes Mellitus, Type 2/blood , Gliclazide/adverse effects , Glycated Hemoglobin/analysis , Glycation End Products, Advanced , Humans , Hypoglycemic Agents/adverse effects , Lipoproteins, LDL/blood , Malondialdehyde/analysis , Nateglinide , Phenylalanine/adverse effects , Prospective Studies , Serum Albumin/analysis , Thiobarbituric Acid Reactive Substances/analysis , Glycated Serum Albumin
19.
J Diabetes Complications ; 18(3): 183-6, 2004.
Article in English | MEDLINE | ID: mdl-15145332

ABSTRACT

Serum 1,5-anhydroglucitol (1,5AG) is a useful glycemic marker in the control of diabetes; however, treated with alpha-glucosidase inhibitors (alpha-GIs), acarbose (Aca) and voglibose (Vog), it tends to show the discrepancy between serum 1,5AG and related glucose levels. Twenty patients were randomly assigned to adding Aca or Vog to the current treatment. We measured serum 1,5AG levels and other parameters of diabetic control before, 2 and 4 weeks after the alpha-GI treatment. We also measured urinary 1,5AG levels using gas chromatography/mass spectrometry (GC/MS). Glycated albumin, Hb(A1c), and fasting plasma glucose (FPG) levels were significantly decreased after 2 and 4 weeks of treatment, and the changes were similar in the two groups. Despite the similar urinary excretion of 1,5AG and other glycemic parameters, serum 1,5AG level was significantly lower in the Aca group than in the Vog group (3.4+/-0.5 vs. 7.9+/-1.2 microg/ml, P<.005; mean+/-S.E.) at the period of 4 weeks. Even in the same glycemic level, the less increase of serum 1,5AG after treatment with Aca might be due to a reduction of intestinal 1,5AG absorption via inhibition of alpha-amylase that features Aca.


Subject(s)
Acarbose/pharmacology , Deoxyglucose/metabolism , Glycoside Hydrolase Inhibitors , Inositol/analogs & derivatives , Inositol/pharmacology , alpha-Glucosidases/pharmacology , Acarbose/therapeutic use , Blood Glucose/chemistry , Blood Glucose/drug effects , Deoxyglucose/blood , Deoxyglucose/urine , Diabetes Mellitus, Type 2/diagnosis , Diabetes Mellitus, Type 2/drug therapy , Diabetes Mellitus, Type 2/metabolism , Forecasting , Glycated Hemoglobin/chemistry , Glycated Hemoglobin/drug effects , Glycated Hemoglobin/metabolism , Glycation End Products, Advanced , Glycosuria , Humans , Inositol/therapeutic use , Serum Albumin/chemistry , Serum Albumin/drug effects , Serum Albumin/metabolism , Sulfonylurea Compounds/therapeutic use , Time Factors , alpha-Glucosidases/therapeutic use , Glycated Serum Albumin
20.
Diabetes Res Clin Pract ; 61(2): 81-8, 2003 Aug.
Article in English | MEDLINE | ID: mdl-12951275

ABSTRACT

Oxidative stress is well known to play a critical role in atherosclerosis. This study investigated an appropriate marker of in vivo oxidative stress and whether it could predict macroangiopathy in diabetes. The lipid composition of erythrocyte membranes was analyzed in 64 type 2 diabetic patients using gas chromatography-mass spectrometry (GC/MS). After 3,5,7-cholestatriene (a cholesterol oxidation product) was detected, the peak height ratio of 3,5,7-cholestatriene to cholesterol was calculated. Carotid artery intima-media thickness (IMT) was measured to evaluate atherosclerosis. The IMT was independently associated with 3,5,7-cholestatriene (P<0.0001), age (P=0.0001), and HbA1c (P=0.05) by stepwise multiple regression analysis (R2=0.416, P<0.0001). When the subjects were divided into groups with or without carotid atherosclerosis, the 3,5,7-cholestatriene level was significantly higher in 37 subjects with atherosclerosis than in 27 subjects without it (0.41+/-0.22 vs. 0.16+/-0.16%, P<0.0001). Among 38 subjects with no clinical manifestations of macroangiopathy and long-term good glycemic control, the 3,5,7-cholestatriene level was also significantly higher in the patients with carotid atherosclerosis than in those without it (0.40+/-0.20 vs. 0.18+/-0.12%, P=0.0003). These data suggest that the 3,5,7-cholestatriene level in erythrocyte membrane lipids may be a useful predictor of subclinical atherosclerosis.


Subject(s)
Carotid Artery Diseases/metabolism , Cholesterol/metabolism , Diabetes Mellitus, Type 2/complications , Erythrocyte Membrane/metabolism , Oxidative Stress , Aged , Biomarkers , Carotid Artery Diseases/etiology , Carotid Artery Diseases/pathology , Carotid Artery Diseases/physiopathology , Diabetes Mellitus, Type 2/physiopathology , Female , Humans , Male , Middle Aged , Oxidation-Reduction , Tunica Intima/pathology , Tunica Media/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...